Genetics history
Landraces, heritage lines and lineages, with evidence labels.
How hybrid 'strains' emerged
Modern drug-type cannabis is mostly a mix of South Asian-derived long-flowering types and Central Asian (Afghan) hashish types, crossed from the 1970s onwards in North America, then distributed by Dutch seed companies from the mid-1980s, and multiplied into thousands of names in clone-driven and legal markets since the 1990s. The broad story is supported by genetics; most specific pedigrees are oral claims with conflicting versions.
Indica, sativa and ruderalis: what the names really mean
Cannabis is one species, Cannabis sativa L., showing different phenotypes. Nearly everything grown today is a hybrid, with a few outlier landraces. Distinct groups, ruderalis included, may have existed long ago, but not today. As a guide to effects or species, indica vs sativa is nonsense: genetic and chemical studies show the labels don't match ancestry or predict chemistry. At most they describe plant shape: leaflet width, structure and flowering time.
Landraces of the world: an overview
Drug-type cannabis landraces developed across South and Central Asia and were carried to Africa, the Middle East and the Americas, where local farmers adapted them over centuries. Genomic work points to an Asian origin of domestication (exact region contested). Many traditional landraces are now endangered by hybrid replacement, and most 'landrace' seed in commerce is better described as heirloom: collected at some point, then maintained elsewhere. Every origin story here is a claim; this article labels the evidence.
Old cannabis wasn't weak: the "so much stronger than 20 years ago" myth
"Cannabis is far stronger than it used to be" is false as a claim about the plant's genetics. Famous hashish, charas and sinsemilla traditions are centuries old and impossible with 5 % plants, and old seed grown well today still tests high. The 'weak old weed' numbers come from seized samples: mostly cheap compressed export brick of leaf, seed and stem, often stored for years before testing, measured with changing methods. The best of what source regions grew was rarely exported. What changed is the market and growing technique: fresh, seedless, indoor flower.
Patents and the gene pool: who can own a cannabis plant?
Cannabis can be protected by US utility patents (covering plants, traits, extracts and methods), plant patents (for asexually reproduced varieties) and plant variety protection certificates (for seed-propagated hemp, since 2019), plus plant breeders' rights in Canada and the EU. Grants are public record. Legal commentators worry that thin prior art and broad claims could fence off parts of a shared gene pool. The open responses are public, dated documentation: prior-art databases, open-source seed pledges and genotype registries. GenetixBay's answer is preservation, GB-ID documentation and open sharing.
Why everything tastes the same: the evidence that commercial cannabis is converging
Growers keep saying modern weed all tastes the same, and the data back them up. A study of nearly 90,000 US lab results found THC-dominant flower falling into just three terpene groups, two of which held about 87 % of samples. Strain names and indica/sativa labels promise far more variety than the chemistry shows, traditional landraces in their home regions are being replaced by introduced hybrids, and retail prices rise with THC rather than aroma. GenetixBay's answer is preservation, documentation with GB-IDs, and open sharing of distinctive lines.
Why strain names are unreliable: what genetic studies show
Several genetic and chemical studies of retail cannabis show that the same strain name often hides different genotypes, that 'indica' and 'sativa' labels don't match genome-wide ancestry, and that potency labels vary by lab. Some names are reasonably consistent, many are not. A name is a claim; a documented source, a GB-ID with evidence and, ultimately, DNA are the evidence.
